Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple III: Leflunomide vs DMARD Combinations in RA
NCT00579878Phase 3Completed
- Sponsor
- University of Nebraska
- Start
- Mar 2001
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of leflunomide in rheumatoid arthritis (RA) (3 arms), sponsored by University of Nebraska. Primary endpoints: American College of Rheumatology 20% Response at 48 weeks and Safety and Efficacy Assessment at 48 weeks. Started Mar 2001; status: completed.
02
Drugs
leflunomide
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00579878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00579878.